Time to onset of sustained ≥50% responder status (SRS) was assessed for the pooled patient population receiving brivaracetam (BRV) 50, 100, or 200 mg/day or placebo in three randomized phase III studies (NCT00464269, NCT00490035, and NCT01261325). Patients were aged ≥16 years with well-characterized focal (partialonset) seizures (FS) uncontrolled by 1-2 concomitant antiepileptic drugs. After an 8-week baseline period, patients received study drug without up-titration for a 12-week (84-day) treatment period. A patient was a sustained ≥50% responder on a particular day if they completed the entire treatment period through day 84 and was a ≥50% responder (based on percent reduction in FS frequency from baseline) both on that day and every successive day until day 84 (end of treatment period). In the pooled efficacy population (N = 1,160), 15.5%, 18.1%, and 19.4% of patients taking BRV 50, 100, or 200 mg/day, respectively, achieved SRS on day 1 versus 6.7% for placebo (p < 0.001). Statistically significant SRS was also achieved for most of the BRV-treated groups in the three separate studies. This suggests that BRV has an early, sustained onset of action in a subset of responders. The incidence of adverse events during the first week was similar to that in the overall treatment period. KEY WORDS: Antiepileptic drugs, Speed of onset, Focal epilepsy, Partial-onset seizures.
The ≥50% responder rate is a common measure of antiepileptic drug (AED) efficacy, defined as the percentage of patients achieving ≥50% reduction in seizure frequency during a specified period. However, there is usually no requirement for this reduction to be sustained, and it gives no indication of seizure frequency distribution. For example, patient A, with seizures spread evenly across the treatment period, and patient B, seizure free from day 1 but with several seizures in the final week of treatment, might both be ≥50% responders despite their different seizure frequency profiles. Furthermore, ≥50% responder rates typically include patients who discontinued during the treatment period, potentially further masking the actual treatment response.
The sustained ≥50% responder rate (SRR) is a more rigorous treatment response measure, defined as a ≥50% reduction in seizure frequency (occurring at any point during the treatment period) maintained without discontinuation of therapy for the remaining treatment period. This allows assessment of the time to onset of sustained ≥50% responder status (SRS), providing insight into the anticipated duration of AED treatment required to achieve ≥50% response.
Brivaracetam (BRV) is an AED of the synaptic vesicle protein 2A (SV2A) ligand class, with high selectivity and affinity for SV2A and rapid brain penetration in animal models. 1, 2 We evaluated time to onset of SRS for adults with focal (partial-onset) seizures (FS) from  three fixed-dose, randomized, double-blind, phase III  studies of BRV (N01253/NCT00464269,   3   N01252/  NCT00490035,  4 and N01358/NCT01261325   5 ). Pooled analysis of these studies provided further evidence for BRV efficacy and tolerability, including "standard" ≥50% responder rates significantly greater than with placebo. 6 Results are reported for the approved BRV therapeutic dosages (50, 100, and 200 mg/day). The favorable tolerability profile of BRV allows initiation without up-titration; consequently, treatment-emergent adverse events (TEAEs) during the first week of treatment were also assessed.
Methods

Study population
The three studies received prior approval by appropriate institutional review bodies and were conducted in accordance with applicable regulatory, ethical, and good clinical practice requirements. Written informed consent was obtained from each patient (or legal guardian) before enrollment.
The design and methodology of each study has been reported previously, and a pooled analysis was recently published. [3] [4] [5] [6] Our post hoc SRS analysis was conducted on the efficacy population from this analysis (N = 1,160): patients ≥16 years with well-characterized FS uncontrolled by 1-2 concomitant AEDs who received BRV 50, 100, or 200 mg/day or placebo, administered twice-daily without up-titration. 6 The studies had 8-week baseline and 12-week (84-day) treatment periods. Patients reporting only nonmotor simple FS (type IA1) at baseline were excluded, as were those receiving BRV 5 or 20 mg/day, as these dosages were not effective. 3, 4 Patients taking concomitant levetiracetam (LEV) in studies N01252 and N01253 were excluded based on an apparent difference in the efficacy profile of BRV in these patients, and exclusion of such patients by design from study N01358.
Assessment of TEAEs included all patients receiving BRV 50, 100, or 200 mg/day or placebo, regardless of LEV status (safety population, N = 1,262).
Sustained responder analysis
The percentages of patients who achieved SRS were estimated by a Kaplan-Meier method. Patients were classified as sustained ≥50% responders on a particular day if they completed the entire treatment period through day 84 and were a ≥50% responder (based on percent reduction in FS frequency [all subtypes] from baseline) both on that day and for every successive day through day 84. By definition, patients discontinuing during the treatment period could not achieve SRS.
Within each BRV treatment group, multiplicity was controlled by assessment of statistical significance versus placebo starting on day 84 and stepping backward by day until either p > 0.05 for any day, or p ≤ 0.05 for all days from day 84 to day 1. The analysis was conducted for the pooled population, and for the three separate studies (excluding patients taking concomitant LEV, or receiving BRV dosages <50 mg/day).
Incidence of, and discontinuations due to, TEAEs were summarized for week 1 of the treatment period. Incidences across the entire treatment period for this population have been reported previously. 6 
Results
Patient demographics and baseline data are reported elsewhere. [3] [4] [5] [6] Briefly, patients were well balanced across treatment groups for most characteristics. Across groups, the mean age range was 37.9-39.7 years and baseline median FS frequency (all subtypes) 7 per 28 days was 8.9-9.6 6 ; across studies the mean duration of epilepsy was 22-24 years. [3] [4] [5] At baseline, most patients reported complex FS (type IB; 84.2% and 78.5% for BRV overall and placebo, respectively), whereas some reported simple FS (type IA) and/or FS evolving to secondary generalized seizures (type IC) 6 (Table S1 ).
In the pooled efficacy population (N = 1,160), statistically significant SRRs were achieved from day 1 for BRV 50, 100, and 200 mg/day (p < 0.001 vs. placebo at day 1 for all treatment groups) (Fig. 1A) . The percentages of patients achieving SRS increased over time for all treatment groups (including placebo), but were consistently greater for BRVtreated than placebo-treated patients (p ≤ 0.003 vs. placebo for all comparisons) ( Table 1) . Kaplan-Meier estimates of the proportion of patients achieving SRS at day 1 were 15.5%, 18.1%, and 19.4% for BRV 50, 100, and 200 mg/day, respectively, versus 6.7% for placebo. Corresponding values on day 7 were 16.8%, 19.9%, and 20.6% versus 7.2% for placebo, and on day 14 were 19.9%, 22.0%, and 24.3% versus 9.6% for placebo. For comparison, the corresponding overall "standard" ≥50% responder rates for this population were 34.2%, 39.5%, and 37.8% for BRV 50, 100, and 200 mg/day, respectively, versus 20.3% for placebo. 6 In the three separate studies, SRS was achieved from day 1 for every BRV dosage, except for 50 mg/day in study N01252 ( Fig. 1B-D) .
In week 1 of the treatment period, 18 of (2.2%) of 803 BRV-and 7 (1.5%) of 459 placebo-treated patients discontinued due to TEAEs, versus 54 (6.7%) BRV-and 18 (3.9%) placebo-treated patients over the entire study duration (safety population, N = 1,262). 6 The most common TEAE leading to discontinuation in the first week was dizziness: six patients receiving BRV versus one receiving placebo. TEAEs reported in ≥5.0% of patients taking BRV (BRV vs. placebo, respectively) during the first week were somnolence (11.2% vs. 4.8%), dizziness (8.0% vs. 2.4%), and fatigue (5.7% vs. 1.1%), consistent with the most common TEAEs across the whole study period. 6 
Discussion
In the pooled analysis, 15.5%, 18.1%, and 19.4% of patients taking BRV 50, 100, and 200 mg/day, respectively, versus 6.7% of patients taking placebo, achieved SRS on treatment day 1 (p < 0.001); that is, these patients achieved ≥50% responder status on day 1 and maintained it for the duration of study treatment. In one of the individual studies, the 50 mg/day dosage did not achieve statistically significant sustained ≥50% response; however, this dosage did not achieve statistically significant efficacy either in this study. 4 Apart from this one exception, analysis of each individual study consistently demonstrated a sustained ≥50% response on day 1 for each BRV dosage.
A study of lamotrigine extended-release adjunctive therapy (N = 243) used similar (but not directly comparable) methodology to determine time to ≥50% reduction in FS frequency following 1 week of study drug exposure. In that analysis, statistical significance versus placebo was achieved on day 18. 8 The SRR is a more rigorous measure of response to treatment than the "standard" ≥50% responder rate. Firstly, the requirement for maintenance of ≥50% response means that only patients with a sustained (rather than transient) response are counted. This reduces the apparent percentage of responders (as demonstrated earlier by comparison with standard ≥50% responder rates), but focuses on patients who are more likely to have a clinically meaningful sustained response. Secondly, a sustained ≥50% responder must complete the entire treatment period, whereas standard ≥50% responder rates typically include patients who discontinued treatment early (e.g., because of side effects). The latter method gives a broader view of drug efficacy, but it is Our results suggest that BRV has a fast onset of action in humans. This may be due to two factors: rapid brain penetration 2 and a favorable tolerability profile allowing initiation at target dose without titration.
In animal models, BRV penetrates the brain faster than LEV.
1,2,9 Maximal pharmacodynamic action after a single oral BRV dose occurs simultaneously with maximal plasma concentration in the audiogenic mouse model. 2 By comparison, LEV peak activity in this model occurs 1 h after peak plasma levels. The brain penetration of BRV and LEV was also studied in rhesus monkeys by measuring displacement of the SV2A positron emission tomography (PET) tracer 11 C-UCB-J. BRV entered the brain within 3 min of intravenous injection, compared with 23 min for LEV. 2 Pharmacokinetic modeling predicts that BRV may enter human brain within minutes of intravenous administration. 2 The rapid BRV brain penetration is due to its lipophilicity (LogD pH7.4 1.04, falling within the optimal range of 1-3), which is similar to that of benzodiazepines and higher than that of LEV. 2 Initiation of BRV at full dosage in phase III studies was possible due to BRV's favorable tolerability profile. In contrast, many AEDs require up-titration to the target dosage to offset tolerability concerns, potentially delaying therapeutic onset. In particular, lamotrigine, topiramate, and perampanel are titrated slowly to minimize potential side effects such as rash (lamotrigine) 10 or cognitive impairment (topiramate), 11 or to monitor for possible neuropsychiatric symptoms (perampanel). 12 Throughout the BRV phase III program, discontinuation due to TEAEs was low (5-8%) across dosage groups. [3] [4] [5] BRV-treated patients were slightly more likely than placebo-treated patients to discontinue due to TEAEs in the first week; this pattern was consistent over the study duration. The most common TEAEs in the first week were the same as for the overall study period, suggesting that there are no additional safety concerns at, or after, treatment initiation.
As with many clinical studies, this analysis is limited by the 12-week treatment period, which is short compared with treatment duration in the real-world setting. Extending the sustained responder analysis to the BRV long-term follow-up studies may provide additional insights into the longer-term maintenance of efficacy. The percentage of patients achieving SRS increased over time, indicating that efficacy was also sustained for patients who responded later in treatment. However, due to the fixed treatment duration, this increase over time may also reflect the shorter time over which later responders must sustain their response in order to achieve SRS. The interpretation of this analysis should therefore generally focus on earlier time points but, for completeness, data are shown over the entire treatment duration. Identification of patients who could respond earlier or later during treatment would have great clinical value; however, this is beyond the scope of our analysis.
Taken together, these results support the fast onset of action and good tolerability of BRV without up-titration. This suggests that patients may benefit from BRV treatment by administration of an effective and tolerable dosage from the first day of treatment, with potential clinical utility where fast onset of action is desirable. For each day, p versus placebo was ≤0.003 for BRV 50 mg/day and <0.001 for BRV 100 and 200 mg/day. Pharma. Dr. Schiemann was an employee of UCB Pharma when the studies and analyses were conducted, and is a current employee of Teva Pharmaceuticals, Frazer, PA, U.S.A. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
